A Post-marketing Real-world Study for Evaluating Effectiveness and Safety of Spartina® (Tirzepatide Manufactured by CinnaGen) in Patients With Obesity and Overweight
Status: Recruiting
Location: See all (14) locations...
Study Type: Observational
SUMMARY
The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered: 1. Is Spartina® (Tirzepatide) effective in the treatment of obesity and overweight? 2. Is Spartina® (Tirzepatide) safe in the treatment of obesity and overweight? In this study, there is no comparison group. Participants receive Spartina® (Tirzepatide)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Male or female ≥18 years of age
• Willingness for signing and having signed the informed consent form
• BMI ≥30 kg/m² or ≥27 kg/m² with ≥1 weight-related comorbidity
Locations
Other Locations
Islamic Republic of Iran
Hajieh Bibi Shahbazian Clinic
RECRUITING
Ahvāz
Mansoor Siavash Dastjerdi Clinic
RECRUITING
Isfahan
Shokoofeh Bonakdaran Clininc
RECRUITING
Mashhad
Behrang Motamed Clinic
RECRUITING
Rasht
Seyed Mojtaba Mehrdad Clinic
RECRUITING
Rasht
Sari Diabetes Research Center
RECRUITING
Sari
Dr. Mohammadhossein Dabbaghmanesh Clinic
RECRUITING
Shiraz
Akbar Aliasgarzadeh Clinic
RECRUITING
Tabriz
Alireza Esteghamati clinic
RECRUITING
Tehran
Farzad Hadaegh Clininc
RECRUITING
Tehran
Imam Khomeini Hospital
RECRUITING
Tehran
Iran University Endocrinology Research Center
RECRUITING
Tehran
Mohammadreza Mohajeri Tehrani Clininc
RECRUITING
Tehran
Khorshid Clinic
RECRUITING
Yazd
Contact Information
Primary
Hamidreza Kafi, Ph.D
Kafi.H@orchidpharmed.com
+982143473000
Backup
Alireza Esteghamati, Professor
esteghamati@tums.ac.ir
+982188417918
Time Frame
Start Date: 2025-11-11
Estimated Completion Date: 2026-04
Participants
Target number of participants: 175
Related Therapeutic Areas
Sponsors
Leads: Cinnagen